Bernhard Moser

European Cytokine Network, Vol.14, No.4, pp. 204-210, 2003

Abstract This article has no abstract. More >

Sender Herschorn

Canadian Journal of Urology, Vol.10, Suppl.1, pp. 23-28, 2003

Abstract Erectile dysfunction (ED) and cardiovascular disease share many of the same risk factors and have some common elements of pathophysiology. Clinically, they often coexist. Another link between the two conditions is that sildenafil, the first oral therapeutic agent effective in treating ED, has been shown to potentiate the hypotensive effects of nitrates, a potentially serious side effect. Nitrates are commonly used in the treatment of coronary artery disease. As such, sildenafil (and, likely, other new phosphodiesterase type 5 [PDE5] inhibitors) is contraindicated in men who use nitrate medications. This article will examine the risk of More >

Gerald B. Brock

Canadian Journal of Urology, Vol.10, Suppl.1, pp. 17-22, 2003

Abstract Oral phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction are preferred by most men, and are recommended in guidelines as first-line therapy, because of convenience, high efficacy, and low rates of side effects. Tadalafil (Cialis™) is a new agent that has been studied in different patient populations. It has a different molecular structure than other PDE5 inhibitors, and a different pharmacologic profile that provides a longer period of effectiveness than other agents. This article will review clinical trials on tadalafil, to provide a comprehensive overview of its efficacy and safety. More >

Serge Carrier

Canadian Journal of Urology, Vol.10, Suppl.1, pp. 12-16, 2003

Abstract The phosphodiesterase enzymes, of at least 11 types, are ubiquitous throughout the body, and perform a variety of functions. Phosphodiesterase type 5 (PDE5) is the predominant enzyme in the corpus cavernosum, and plays a crucial role in penile erection. Inhibitors of PDE5 are the most effective oral agents in the treatment of erectile dysfunction. Sildenafil, tadalafil, and vardenafil are all potent inhibitors of PDE5 and show the same mechanism of action, although they have some pharmacological differences that may translate into varying clinical effects. More >

Luc Valiquette

Canadian Journal of Urology, Vol.10, Suppl.1, pp. 7-11, 2003

Abstract Over the last three decades, there has been a significant increase in our understanding of the physiologic mechanisms responsible for erectile dysfunction. Erectile dysfunction has become a topic of considerable media and societal interest and acceptance. Paralleling the increase in knowledge has been an explosion in therapeutic options. This article will evaluate the therapeutic options, from a historical perspective of what has been available, and outline the progress that has been made. More >

Peter Pommerville

Canadian Journal of Urology, Vol.10, Suppl.1, pp. 2-6, 2003

Abstract Sexual function is a central part of a man’s identity, helping to define who he is, and how he feels about himself. It is also a key determinant of relationship health. Erectile dysfunction (ED) threatens all of this, and is thus an important topic in male health. Erectile dysfunction is common around the world, especially in older men. Risk factors for ED overlap significantly with those for cardiovascular disease and endothelial dysfunction, especially diabetes. More >

Gerald B. Brock

Canadian Journal of Urology, Vol.10, Suppl.1, pp. 1-1, 2003

Abstract This article has no abstract. More >

Jonathan E. Chan, Anil Kapoor

Canadian Journal of Urology, Vol.10, No.3, pp. 1912-1913, 2003

Abstract Herpes zoster (HZ) infection has been reported as a rare cause of acute urinary retention. HZ infection involving sacral, thoracolumbar, and rarely high thoracic dermatomes is believed to occasionally cause motor and sensory neuropathy of the bladder. This is specifically achieved by the interruption of the detrusor reflex causing subsequent bladder atonia. As the course and management of this entity is quite benign, HZ should remain a diagnostic consideration in the management of urinary retention. We report a case of acute urinary retention of approximately 2.5 liters associated with HZ infection and review the proposed More >

Daniel J. Caruso, Murali K. Ankem, John Riordan, Joseph G. Barone

Canadian Journal of Urology, Vol.10, No.3, pp. 1910-1911, 2003

Abstract Prune Belly Syndrome developed urinary ascites secondary to forniceal rupture. Treatment consisted of bilateral cutaneous pyelostomies. Even though most children with Prune Belly Syndrome respond to lower urinary tract drainage, a cutaneous pyelostomy may be necessary when the ureters are tortuous and do not drain adequately following bladder decompression. More >

Todd M. Webster, Ronald G. Gerridzen

Canadian Journal of Urology, Vol.10, No.3, pp. 1905-1909, 2003

Abstract Introduction: Numerous management strategies are available for stress urinary incontinence, a significant problem for many women. The pubovaginal sling (PVS) with rectus fascia has proven efficacy with minimal morbidity. Historically, patients were admitted for an average of 4 days at the Ottawa Hospital. Since November 2001, patients have spent one night in hospital thereby cutting their total length of stay to less than 24 hours. This study assesses the feasibility of this approach.
Materials and methods: Ethics approval was obtained. All patient charts were reviewed retrospectively. Exclusion criteria included women booked for combined procedures or patient refusal.… More >